IDBS E-WorkBook for Chemistry Enables Achillion Pharmaceuticals to Go Paperless
Boston, US, New Haven, US & Guildford, UK, February 8, 2017 – Today, IDBS, a leading global provider of advanced software for R&D companies, announced that New Haven-based Achillion Pharmaceuticals has implemented the IDBS E-WorkBook for electronic laboratory data capture.
Atul Agarwal, Executive Director at Achillion, said: “IDBS was a standout choice of electronic laboratory notebook (ELN) provider because of its forward-thinking vision, flexibility and first-class customer service. We were looking for a provider with the ability to scale-up as we continue to grow and bring new therapeutics to trial, and IDBS has the agility and openness to do so.”
Using the IDBS E-WorkBook platform will help Achillion improve data capture, knowledge sharing and management across multiple sites.
Ian Peirson, Head of Product Planning at IDBS, said: “IDBS is proud to support Achillion’s noble objective of discovering, developing and marketing new treatments for diseases. It is inspiring to know that E-WorkBook and the Chemistry module will play a part in helping Achillion to achieve its objectives.”
The E-WorkBook platform will give Achillion scientists a clear and intuitive interface to work with whilst synthesising and testing new discovery compounds.
IDBS’ strategic partnership with ChemAxon also provides Achillion with world-leading technology for the robust representations of chemical and biological molecules, enabling Achillion scientists to ensure their data is stored in a modern and industry-standard data format.
Furthermore, IDBS’ ability to provide a combination of secure on-premise and SaaS solutions cemented Achillion’s decision to transition to a 100% electronic laboratory notebook with IDBS.
About Achillion
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at www.achillion.com
About IDBS
IDBS is a leading global provider of advanced software for research and development (R&D) organizations to securely capture, manage, share and exploit structured and unstructured data. Our technology and domain expertise enable users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Our diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.
Founded in 1989, IDBS is headquartered in the United Kingdom with offices across Europe, Asia and the United States. IDBS remains a privately held company employing over 250 staff across the world and serving over 50,000 researchers in 25 countries – including over 80% of the top twenty pharmaceutical companies.
For more information, please visit www.idbs.com or follow us on Twitter @IDBSsoftware.
About ChemAxon
ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. We focus on active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA and sales and support offices in Europe, Japan and across North America.
For further information, please visit www.chemaxon.com or follow us on Twitter @chemaxon.
